206 related articles for article (PubMed ID: 37291458)
1. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
Goncalves BG; Banerjee IA
J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
[TBL] [Abstract][Full Text] [Related]
2. An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors.
Mitchell SM; Heise RM; Murray ME; Lambo DJ; Daso RE; Banerjee IA
Mol Divers; 2024 Apr; 28(2):817-849. PubMed ID: 36847923
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.
Lambo DJ; Lebedenko CG; McCallum PA; Banerjee IA
Mol Divers; 2023 Feb; 27(1):389-423. PubMed ID: 35505173
[TBL] [Abstract][Full Text] [Related]
4. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors.
Rico MI; Lebedenko CG; Mitchell SM; Banerjee IA
Mol Divers; 2022 Oct; 26(5):2717-2743. PubMed ID: 35037187
[TBL] [Abstract][Full Text] [Related]
6. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
7. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
Baggio C; Udompholkul P; Gambini L; Pellecchia M
J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527
[TBL] [Abstract][Full Text] [Related]
8. In silico studies of interactions of peptide-conjugated cholesterol metabolites and betulinic acid with EGFR, LDR, and N-terminal fragment of CCKA receptors.
Bashant MM; Mitchell SM; Hart LR; Lebedenko CG; Banerjee IA
J Mol Model; 2021 Dec; 28(1):16. PubMed ID: 34961887
[TBL] [Abstract][Full Text] [Related]
9. Conformational Clamping by a Membrane Ligand Activates the EphA2 Receptor.
Westerfield JM; Sahoo AR; Alves DS; Grau B; Cameron A; Maxwell M; Schuster JA; Souza PCT; Mingarro I; Buck M; Barrera FN
J Mol Biol; 2021 Sep; 433(18):167144. PubMed ID: 34229012
[TBL] [Abstract][Full Text] [Related]
10. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.
Udompholkul P; Baggio C; Gambini L; Sun Y; Zhao M; Hoffman RM; Pellecchia M
Molecules; 2021 Jun; 26(12):. PubMed ID: 34204178
[TBL] [Abstract][Full Text] [Related]
11. Design and analysis of EphA2-SAM peptide ligands: A multi-disciplinary screening approach.
Mercurio FA; Di Natale C; Pirone L; Marasco D; Calce E; Vincenzi M; Pedone EM; De Luca S; Leone M
Bioorg Chem; 2019 Mar; 84():434-443. PubMed ID: 30576907
[TBL] [Abstract][Full Text] [Related]
12. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
Barile E; Wang S; Das SK; Noberini R; Dahl R; Stebbins JL; Pasquale EB; Fisher PB; Pellecchia M
ChemMedChem; 2014 Jul; 9(7):1403-12. PubMed ID: 24677792
[TBL] [Abstract][Full Text] [Related]
14. Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.
Hunt HL; Goncalves BG; Biggs MA; Rico MI; Murray ME; Lebedenko CG; Banerjee IA
Mol Divers; 2024 Jan; ():. PubMed ID: 38240950
[TBL] [Abstract][Full Text] [Related]
15. Targeting EphA2-Sam and Its Interactome: Design and Evaluation of Helical Peptides Enriched in Charged Residues.
Mercurio FA; Marasco D; Di Natale C; Pirone L; Costantini S; Pedone EM; Leone M
Chembiochem; 2016 Nov; 17(22):2179-2188. PubMed ID: 27763725
[TBL] [Abstract][Full Text] [Related]
16. Structural investigation of a C-terminal EphA2 receptor mutant: Does mutation affect the structure and interaction properties of the Sam domain?
Mercurio FA; Costantini S; Di Natale C; Pirone L; Guariniello S; Scognamiglio PL; Marasco D; Pedone EM; Leone M
Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1095-1104. PubMed ID: 28602916
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship analysis of peptides targeting the EphA2 receptor.
Mitra S; Duggineni S; Koolpe M; Zhu X; Huang Z; Pasquale EB
Biochemistry; 2010 Aug; 49(31):6687-95. PubMed ID: 20677833
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell.
Gambini L; Salem AF; Udompholkul P; Tan XF; Baggio C; Shah N; Aronson A; Song J; Pellecchia M
ACS Chem Biol; 2018 Sep; 13(9):2633-2644. PubMed ID: 30110533
[TBL] [Abstract][Full Text] [Related]
19. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
20. Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.
Heinzlmeir S; Kudlinzki D; Sreeramulu S; Klaeger S; Gande SL; Linhard V; Wilhelm M; Qiao H; Helm D; Ruprecht B; Saxena K; Médard G; Schwalbe H; Kuster B
ACS Chem Biol; 2016 Dec; 11(12):3400-3411. PubMed ID: 27768280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
